Comparison of Dietary Phosphate Absorption After Single Doses of Lanthanum Carbonate and Sevelamer Carbonate in Healthy Volunteers: A Balance Study

被引:34
|
作者
Martin, Patrick [1 ]
Wang, Phillip [1 ]
Robinson, Antoine [1 ]
Poole, Lynne [2 ]
Dragone, Jeffrey [1 ]
Smyth, Michael [2 ]
Pratt, Raymond [1 ]
机构
[1] Shire Pharmaceut, Wayne, PA 19087 USA
[2] Shire Pharmaceut, Basingstoke, Hants, England
关键词
Chronic kidney disease; clinical trial; lanthanum carbonate; phosphate binder; sevelamer carbonate; CORONARY-ARTERY CALCIFICATION; HEMODIALYSIS-PATIENTS; CALCIUM-CARBONATE; IN-VITRO; PHOSPHORUS; MORTALITY; BINDERS; HYPERPHOSPHATEMIA; PROGRESSION; METABOLISM;
D O I
10.1053/j.ajkd.2010.11.028
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Lanthanum carbonate and sevelamer carbonate are noncalcium phosphate binders used to treat hyperphosphatemia in patients with chronic kidney disease. This is the first study to compare phosphate absorption from a standardized meal ingested with a typical clinical dose of these binders. Study Design: Randomized open-label crossover study. Settings & Participants: Healthy volunteers were confined to a clinical research center during 4 study periods. Of 31 volunteers randomly assigned, 19 completed all treatments and 18 were analyzed in the pharmacodynamic set (1 was excluded because of vomiting). Intervention: Participants were assigned in random order to meal alone, meal plus lanthanum carbonate (1 tablet containing 1,000 mg of elemental lanthanum), and meal plus sevelamer carbonate (three 800-mg tablets). The gastrointestinal tract was cleared, the meal was ingested (+/- treatment), and rectal effluent was collected. In a fourth period, volunteers repeated the study procedures while fasting. Outcomes: The primary end point, net phosphate absorption, was analyzed using a mixed-effect linear model. Measurements: Phosphorus content of effluent and duplicate meal samples were measured using inductively coupled plasma-optical emission spectroscopy. Results: The standard meal contained similar to 375 mg of phosphate, 75% of which was absorbed (net absorption, 281.7 +/- 14.1 mg [adjusted mean +/- standard error]). Lanthanum carbonate decreased net phosphate absorption by 45% (net absorption, 156.0 +/- 14.2 mg) compared with 21% (net absorption, 221.8 +/- 14.1 mg) for sevelamer carbonate (P < 0.001). Lanthanum carbonate bound 135.1 +/- 12.3 mg of phosphate, whereas sevelamer carbonate bound 63.2 +/- 12.3 mg, a 71.9-mg difference (95% CI, 40.0-103.8; P < 0.001). Per tablet, this equates to 135 mg of phosphate bound with lanthanum carbonate versus 21 mg with sevelamer carbonate. Limitations: A single-dose study. Conclusions: In healthy volunteers, 1,000 mg of lanthanum carbonate decreased phosphate absorption by 45% compared with a 21% decrease with 2,400 mg of sevelamer carbonate. Am J Kidney Dis. 57(5): 700-706. (C) 2011 by the National Kidney Foundation, Inc.
引用
收藏
页码:700 / 706
页数:7
相关论文
共 32 条
  • [21] PILOT-STUDY OF THE PHARMACOKINETICS OF METHYLPREDNISOLONE AFTER SINGLE AND MULTIPLE INTRAVENOUS DOSES OF METHYLPREDNISOLONE SODIUM SUCCINATE AND METHYLPREDNISOLONE SULEPTANATE TO HEALTHY-VOLUNTEERS
    FERRY, JJ
    DELLACOLETTA, AA
    WEBER, DJ
    VANDERLUGT, JT
    JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (11): : 1109 - 1115
  • [22] A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [14C] Prucalopride After a Single Oral Dose in Healthy Volunteers
    Flach, Stephen
    Scarfe, Graeme
    Dragone, Jeffrey
    Ding, Jie
    Seymour, Mark
    Pennick, Mike
    Pankratz, Todd
    Troy, Steven
    Getsy, Jay
    CLINICAL THERAPEUTICS, 2016, 38 (09) : 2106 - 2115
  • [23] Pharmacokinetic Profiles of Artesunate After Single Intravenous Doses at 0.5, 1, 2, 4, and 8 mg/kg in Healthy Volunteers: A Phase I Study
    Li, Qigui
    Cantilena, Louis R.
    Leary, Kevin J.
    Saviolakis, George A.
    Miller, R. Scott
    Melendez, Victor
    Weina, Peter J.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2009, 81 (04): : 615 - 621
  • [24] Assessment of Pharmacodynamic Equivalence and Tolerability of Lanthanum Carbonate Oral Powder and Tablet Formulations: A Single-Center, Randomized, Open-Label, 2-Period Crossover Study in Healthy Subjects
    Pierce, David
    Hossack, Stuart
    Robinson, Antoine
    Zhang, Pinggao
    Martin, Patrick
    CLINICAL THERAPEUTICS, 2012, 34 (06) : 1290 - 1300
  • [25] SAFETY, TOLERANCE, AND PRELIMINARY PHARMACOKINETICS OF NEFAZODONE AFTER ADMINISTRATION OF SINGLE AND MULTIPLE ORAL DOSES TO HEALTHY ADULT MALE-VOLUNTEERS - A DOUBLE-BLIND, PHASE-I STUDY
    BARBHAIYA, RH
    MARATHE, PH
    GREENE, DS
    MAYOL, RF
    SHUKLA, UA
    GAMMANS, RR
    PITTMAN, KA
    ROBINSON, D
    JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (10): : 974 - 984
  • [26] A Pharmacokinetic Comparison of Single Doses of Once-Daily Cyclobenzaprine Extended-Release 15 mg and 30 mg: A Randomized, Double-Blind, Two-Period Crossover Study in Healthy Volunteers
    Darwish, Mona
    Chang, Steven
    Hellriegel, Edward T.
    CLINICAL THERAPEUTICS, 2009, 31 (01) : 108 - 114
  • [27] Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers
    Baakman, Anne C.
    Zuiker, Rob
    van Gerven, Joop M. A.
    Gross, Nicholas
    Yang, Ronghua
    Fetell, Michael
    Gershon, Ari
    Gilgun-Sherki, Yossi
    Hellriegel, Edward
    Spiegelstein, Ofer
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (05) : 970 - 985
  • [28] GlycoPEGylated filgrastim XM22 demonstrates dose-dependent activity in comparison to pegfilgrastim in a dose-escalating study in healthy volunteers after body-weight dependent single dose
    Lubenau, Heinz
    Pokorny, Rolf
    Lopez-Lazaro, Luis
    Bias, Peter
    Wallin, Bruce
    Hinderer, Walter
    Maly, Anne-Katrin
    Seiberling, Michael
    BLOOD, 2007, 110 (11) : 89B - 89B
  • [29] Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Phase 1 Study
    Cattaneo, Dario
    Cossu, Maria V.
    Fucile, Serena
    Riva, Agostino
    Baldelli, Sara
    Meraviglia, Paola
    Landonio, Simona
    Impagnatiello, Caterina
    Resnati, Chiara
    Galli, Massimo
    Clementi, Emilio
    Capetti, Amedeo
    Rizzardini, Giuliano
    Gervasoni, Cristina
    THERAPEUTIC DRUG MONITORING, 2015, 37 (01) : 119 - 125
  • [30] Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations After Single Subcutaneous Administration: An Open-Label, Sequence-Randomized, Two-Treatment Crossover Study in Healthy Korean Male Volunteers
    Kim, Tae-Eun
    Kim, Kyu-Pyo
    Kim, Bo-Hyung
    Shin, Sang-Goo
    Jang, In-Jin
    Yu, Kyung-Sang
    CLINICAL THERAPEUTICS, 2010, 32 (11) : 1968 - 1976